Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

HGH Fragment

Also known as: HGH Frag 176-191 · HGH Fragment 176-191

Growth hormonePreclinicalPubMed records: 20count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O HGH Fragment 176-191 é um fragmento sintético da porção C-terminal do hormônio do crescimento humano, correspondendo aos aminoácidos na posição 176 a 191. Este fragmento retém a atividade lipolítica (queima de gordura) do GH completo, mas sem os efeitos anabólicos no músculo ou os efeitos diabetogênicos (resistência insulínica) do GH intacto. É essencialmente a 'parte queima-gordura' do GH isolada. Original in PT-BR

HGH Fragment is catalogued under Growth hormone. 4 Eagle articles in this library reference this compound.

Category
Growth hormone
Research stage
Preclinical — Pré-Clínico (Limitado) Original in PT-BR
PubMed records
20 (count from PubMed, not curated)
Eagle articles on this compound
4 Eagle articles

Mechanism

Fragmento C-terminal do GH (aminoácidos 176-191) — mobiliza gordura SEM efeitos anabólicos/diabetogênicos do GH Original in PT-BR

O HGH Frag 176-191 mimetiza a ação lipolítica do GH ao ativar a β3-adrenoceptor no tecido adiposo, estimulando a lipólise (quebra de triglicerídeos em ácidos graxos livres) sem afetar a sensibilidade insulínica ou promover crescimento muscular (PMID: 11713213). Diferentemente do GH completo ou de secretagogos como CJC-1295/Ipamorelin, o fragmento não eleva IGF-1 de forma significativa. Isso limita seus efeitos benéficos sobre reparo, sono e composição corporal geral, mas o torna uma opção mais limpa para quem busca exclusivamente perda de gordura. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
221231-10-3
Molecular formula
C₇₈H₁₂₅N₂₃O₂₃S₂
Molecular weight
1817,12 g/mol pt-BR notation
Sequence
YLRIVQCRSVEGSCGF
Amino acids
16 counted from the sequence above
Solubility
Água bacteriostática Original in PT-BR
Stability
Estável reconstituído por 21 dias refrigerado Original in PT-BR
Half-life
~30 minutos Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
2–4 semanas para efeitos perceptíveis na composição corporal Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

40/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Demonstrou que o fragmento 176-191 estimula lipólise em adipócitos humanos sem afetar sensibilidade insulínica ou produzir efeitos de GH completo. Original in PT-BR

    PMID: 11713213Year: 2001Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Em modelo animal de obesidade, o fragmento reduziu peso corporal e massa gordurosa sem efeitos diabetogênicos do GH. Original in PT-BR

    PMID: 12435775Year: 2003Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Leve irritação no sítio de injeção
  • Sonolência transitória (raro)

Serious

  • Perfil de segurança limitado — poucos estudos humanos
  • Hipoglicemia teórica se combinado com outros agentes hipoglicemiantes

Contraindications

  • Diabetes tipo 1 (risco de hipoglicemia)
  • Gravidez ou amamentação
  • Câncer ativo

Warnings

  • Evidência mais limitada que secretagogos de GH completos
  • Não é substituto de dieta e exercício — complemento

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for HGH Fragment.

Lab tests named in the source

  • Glicemia de jejum
  • Insulina
  • Perfil lipídico
  • Composição corporal (DEXA)

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose Padrão
250–500 mcg SC, 1–2x/dia Original in PT-BR
Frequência
1–2x ao dia Original in PT-BR
Rota
SC (abdominal preferencial) Original in PT-BR
Ciclo
8–12 semanas Original in PT-BR
Timing
Manhã em jejum e/ou pré-aeróbico Original in PT-BR
UI na Seringa
10 UI = 250 mcg (frasco 5mg / 2mL BAC) Original in PT-BR

Vial sizes: 2mg · 5mg — Peptide Calculator

Interactions

This section brings together two origins. The ones Eagle wrote come from its own curated library, one by one; the rest come from the imported reference material, which records one label and one comment per pair and no source. Neither kind carries a PMID, a population or model, or a degree of certainty. Eagle did not verify the imported ones and does not endorse them. «Compatible», «Caution» and «Avoid» are not an Eagle authorisation or prohibition, and none of this is medical advice.

Compatible

Caution

Related

← Back to knowledge area